Premier Alternatives

Kernalbio

Drug Discovery · Cambridge, MA · Founded 2016 · Privately Held (backing)

Developer of mRNA therapies designed to develop curative immunotherapies for cancers and COVID-19. Kernalbio is based in Cambridge, MA and was founded in 2016. It was valued at $111 million at its later-stage round in Jul 2022, the last priced event on record. It has raised $36.1 million across 1 recorded round; the latest was a $25 million Series A in Jul 2022.

PMV mark · valuation
$110.5M
Oct 2026
Priced at
its later-stage round
Jul 2022
Total raised
$36.1M
Last round
Later Stage VC (Series A)
Jul 2022
How much has Kernalbio raised?
$36.1Macross 1 recorded rounds · Jul 2022 – Jul 2022

Most recently, Kernalbio raised $25.0M in its Later Stage VC (Series A) (Jul 2022).

Free account
More of Kernalbio with a free account
  • ·The complete investor list: 47 names
  • ·Watch Kernalbio: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Kernalbio round by round

1 rounds
Jul 2022Later Stage VC (Series A)$25.0M▮
+ 1 more investors · free account

How much has Kernalbio raised?

Kernalbio has raised $36.1 million in total; 1 of its rounds is on record. The largest on record was a $25 million Series A in Jul 2022.

Kernalbio investors

47 investors are on record for Kernalbio, including Y Combinator, MassChallenge, Astir Ventures and Gaingels. By type, the record holds 6 venture capital firms. The Series A in Jul 2022 drew 20 investors.

For fundraisers
Raising for a company like Kernalbio?

47 investors have backed Kernalbio — start your target list with the firms already writing checks in drug discovery.

See all 47 investors →

Frequently asked about Kernalbio

How much has Kernalbio raised?
Kernalbio has raised $36.1M in total across 1 recorded funding rounds.
When was Kernalbio's last funding round?
Kernalbio's most recent recorded round was Later Stage VC (Series A) in Jul 2022, raising $25.0M.